SMMT — Summit Therapeutics Inc. stock price, charts and financials

QT42Summit Therapeutics Inc.

Summit Therapeutics Inc. (NASDAQ: SMMT) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
17.72
+0.42+2.43%
OverviewShort InterestFilings
SMMTQT42Summit Therapeutics Inc.·NASDAQ
17.72+2.43%
News
Up 2.4% — Tracking Baker Brothers' Portfolio: Q2 2026 Update (SeekingAlpha).
Medium confidence
TA
Loading chart...
Signal & projected range
Analyst consensus risingHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
EXEL+3.01%$58.49ASND-3.49%$239.04BBIO-1.45%$67.31NBIX+1.56%$151.83JAZZ+0.10%$243.84HALO+1.14%$109.68BMRN+0.54%$65.08MDGL+1.00%$534.40
Snapshot
Index-P/E196.89EPS (ttm)0.09Insider Own-Shs Outstand797.75MPerf Week4.24%
Market Cap14.14BForward P/E-EPS next Y-1.16Insider Trans0.65%Shs Float110.35MPerf Month38.22%
Enterprise Value13.47BPEG-EPS next Q-0.28Inst Own-Short Float5.18%Perf Quarter25.94%
Income7.00MP/S-EPS this Y-1420.48%Inst Trans-Short Ratio7.85Perf Half Y13.59%
Sales57.00MP/B22.44EPS next Y2.37%ROA-113.81%Short Interest41.33MPerf YTD1.32%
Book/sh0.79P/C20.46EPS next 5Y-ROE-204.33%52W High29.23 -39.38%Perf Year-2.21%
Cash/sh0.87P/FCF-EPS past 3/5Y-ROIC-134.14%52W Low12.07 46.81%Perf 3Y889.94%
Dividend Est.-EV/EBITDA-Sales past 3/5Y-Gross Margin0.00%Volatility4.64% 5.60%Perf 5Y168.89%
Dividend TTM-EV/Sales-EPS Y/Y TTM136.00%Oper. Margin0.00%ATR (14)0.96Perf 10Y165.67%
Dividend Ex-Date-Quick Ratio6.96Sales Y/Y TTM-Profit Margin0.00%RSI (14)63.38Recom2.35
Dividend Gr. 3/5Y-Current Ratio6.96EPS Q/Q63.16%SMA2013.85%Beta-1.61Target Price26.86
Payout0.00%Debt/Eq0.03Sales Q/Q-SMA5021.23%Rel Volume1.20Prev Close17.30
Employees265LT Debt/Eq0.03EarningsOct 19SMA2007.88%Avg Volume5.13MPrice17.72
IPO DateMar 05, 2015Option/ShortYes / YesEPS/Sales Surpr.-2.04% -Net Debt/EBITDA0.47Volume6,133,091Change2.43%
Analyst Ratings
DateActionAnalystRatingTarget
Sep-09-26ReiteratedSummit Redstone Partners$12 → $25
Sep-09-26UpgradeJefferiesHold → Buy
Sep-08-26ReiteratedUBS$33
Aug-25-26ReiteratedSummit Redstone Partners$18 → $12
Aug-25-26UpgradeBernsteinUnderperform → Market Perform
Aug-12-26UpgradeLeerink PartnersUnderperform → Market Perform
Jul-24-26ReiteratedJefferiesHold$17 → $15
Jul-24-26ReiteratedStifel Nicolaus$45 → $38
Jul-24-26ReiteratedGuggenheimBuy$38
May-22-26DowngradeHC Wainwright & Co.Buy → Neutral
Latest News· Times ET
Sep-16-26
Sep-16-2603:46PM
Tracking Baker Brothers' Portfolio: Q2 2026 UpdateSeekingAlpha
Sep-15-26
Sep-15-2602:00AM
Updated HARMONi Data Presented at WCLC 2026 Demonstrate Consistent Overall Survival Results with Ivonescimab Plus Chemotherapy in Western and Asian Patientsbusinesswire.com
Sep-13-26
Sep-13-2604:00AM
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Condugurufocus.com
03:00AM
Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso's HARMONi-2 Study Conducted in Chinabusinesswire.com
Sep-09-26
Sep-09-2601:22PM
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25Benzinga
Sep-04-26
Sep-04-2611:48PM
Bank of New York Mellon Corp Takes $6.28 Million Position in Summit Therapeutics PLC $SMMTdefenseworld.net
07:53AM
SMMT Stock Soars on NSCLC Drug Survival Data Beating Keytruda in Chinazacks.com
Sep-03-26
Sep-03-2603:35PM
Summit Therapeutics: The High Stakes Of Translating China Clinical Data To The U.S.SeekingAlpha
06:57AM
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Studybenzinga.com
02:22AM
November 14 Is The Make-Or-Break Moment For Summit Therapeutics' Cancer Betseekingalpha.com
Sep-02-26
Sep-02-2601:41PM
Ivonescimab Monotherapy Demonstrates Statistically Significant Overall Survival Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in HARMONi-2 Study Conducted by Akeso in Chinabusinesswire.com
Aug-27-26
Aug-27-2609:15AM
SMMT Rises on Akeso's Win in Phase III Biliary Tract Cancer Studyzacks.com
Aug-26-26
Aug-26-2612:43PM
Summit Therapeutics: Signals Of Moving Past Lung Cancer (Rating Upgrade)SeekingAlpha
09:46AM
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapybenzinga.com
Aug-25-26
Aug-25-2602:05PM
Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORRBenzinga
Company

Summit Therapeutics Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing therapeutic solutions, primarily targeting infectious diseases across the United States and Latin America. The company's clinical development pipeline is heavily concentrated on therapies for Clostridioides difficile infection (CDI). Its flagship product candidate, ridinilazole, is an orally administered small molecule antibiotic currently advancing through Phase III clinical trials as a treatment for CDI. Beyond its lead asset, Summit Therapeutics is also progressing SMT-738, designed to combat multidrug-resistant infections, notably carbapenem-resistant Enterobacteriaceae (CRE). Additionally, its DDS-04 series represents a potential therapeutic avenue for various infections caused by the Enterobacteriaceae family of bacteria. Established in 2003, the company maintains its headquarters in Cambridge, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
1/31/2019
Total Revenue
5700——————
Cost of Goods Sold Incl. D&A
000——————
Gross Profit
5700——————
Selling, General and Administrative Excl. Other1455748——————
Research and Development38538132——————
Other Operating Expense2-11——————
Operating Income22-1,094-181——————
Interest Expense009——————
Unusual Expense
—————————
Non-Operating Income (Expense)-91512——————
Net Income Before Taxes13-1,080-177——————
Income Taxes
-300——————
Consolidated Net Income7-1,080-177——————
Net Income From Continuing Operations15-1,080-177——————
Net Income7-1,080-177——————
EPS (Recurring)0.09-1.44-0.25——————
EPS (Basic, Before Extraordinaries)0.09-1.44-0.25——————
EPS (Diluted)0.09-1.44-0.25——————
EBITDA-2-1,079-168——————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
196.89————————
Price To Sales Ratio
47.56————————
Gross Margin
100.00————————
Operating Margin
38.60————————
Net Margin
12.28————————
Shares Outstanding153748714——————
Market Capitalization2,71113,08312,745——————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$31.85$26.36$20.88$15.39$9.90● Close Price0.00M25.90M51.81M77.71M103.62MUSD Trades VolumeSepOctNovDec2026FebMarAprMayJunJulAugSep
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Zanganeh MahkamCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12
DUGGAN ROBERT WCo-Chief Executive OfficerJun 12 '26Buy13.123,810,00049,987,200573,883,879Jun 12
Soni Manmeet SinghCOO and CFOJun 04 '26Buy14.4550,000722,2503,123,603Jun 04
DUGGAN ROBERT WCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04
Zanganeh MahkamCo-Chief Executive OfficerJun 04 '26Buy14.60100,0001,460,00025,824,474Jun 04
Xia YuDirectorOct 21 '25Buy18.74533,6179,999,98332,057,147Oct 23
DUGGAN ROBERT WCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23
Zanganeh MahkamCo-Chief Executive OfficerOct 21 '25Buy18.7426,680499,98376,680Oct 23
Zanganeh MahkamCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11
DUGGAN ROBERT WCo-Chief Executive OfficerSep 11 '25Buy18.075,00090,350556,093,090Sep 11
Zanganeh MahkamCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11
DUGGAN ROBERT WCo-Chief Executive OfficerSep 10 '25Buy17.68333,3945,894,406556,088,090Sep 11
Zanganeh MahkamCo-Chief Executive OfficerMay 30 '25Option Exercise2.6474,545196,799555,754,696Jun 02
DUGGAN ROBERT WCo-Chief Executive OfficerMay 30 '25Option Exercise2.6474,545196,799555,754,696Jun 02
Zanganeh MahkamCo-Chief Executive OfficerApr 08 '25Option Exercise1.587,970,11012,592,774555,680,151Apr 09
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.